XENCOR INC · Data as of 2026-09-08
H2 2026
Zenas announced that it submitted a BLA to the FDA for the treatment of IgG4-RD in May 2026 and anticipates submitting a Marketing Authorization Application to the European Medicines Agency in the second half of 2026.Source filing
2H26
• Xencor plans to present Phase 1 dose-escalation data to define a recommended Phase 3 target dose in 2H26 and evaluate plans for a pivotal study of XmAb541 during 2027.Source filing
Late 2026
Enrollment expectations continue to support a XENITH-UC blinded interim analysis around year-end 2026 and reaching the primary endpoint of the 12-week induction period in 2H27.Source filing
1H27
Xencor initiated a first-in-human study of XmAb412 in the third quarter of 2026 and plans to present initial data from the study in 1H27.Source filing
in 2027
The Phase 1 dose-escalation study of XmAb541 and XmAb808 is ongoing and expected to reach the combination's target dose range in 2027.Source filing
2H27
XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27Source filing
2H26
Xencor plans to provide an update on progress achieved in the Phase 1b study of plamotamab in RA in 2H26.Source filing
2H26
Xencor plans to provide an update on progress achieved in the Phase 1 study of XmAb657 in 2H26.Source filing
Oct 23–Oct 27
XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or plannedSource filing